12 Health Care Stocks Moving In Wednesday's Intraday Session
Portfolio Pulse from Benzinga Insights
Several health care stocks experienced significant price movements during Wednesday's intraday session. Notable gainers included Tharimmune, Ensysce Biosciences, Xilio Therapeutics, Omnicell, CVRx, and CalciMedica. On the losing side, Applied DNA Sciences, AnaptysBio, Sage Therapeutics, Option Care Health, Cormedix, and Hims & Hers Health saw declines. The movements were influenced by recent earnings reports and market reactions.
October 30, 2024 | 4:31 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
CalciMedica's stock rose by 31.66% to $5.17, reflecting positive market sentiment.
The stock's rise suggests positive sentiment or developments, which could continue to drive interest and price increases.
CONFIDENCE 80
IMPORTANCE 60
RELEVANCE 70
POSITIVE IMPACT
CVRx's stock increased by 32.83% to $14.27, likely due to positive Q3 earnings.
The stock's increase is likely a reaction to favorable Q3 earnings, indicating strong performance or outlook.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Ensysce Biosciences' stock rose by 51.76% to $0.63, reflecting a positive market reaction.
The significant price increase suggests positive sentiment or news, which could lead to continued upward momentum.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
POSITIVE IMPACT
Omnicell's stock rose by 33.25% to $53.46 following the release of its Q3 earnings.
The stock's rise is directly linked to the Q3 earnings report, suggesting positive results or outlook that could sustain the upward trend.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
POSITIVE IMPACT
Tharimmune's stock surged by 106.1% to $4.18, significantly increasing its market value.
Tharimmune's stock saw a massive increase, indicating strong investor interest or positive news. This is likely to attract more attention and potentially further price increases.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Xilio Therapeutics' stock increased by 35.29% to $1.34, indicating strong investor interest.
The rise in stock price suggests positive developments or investor sentiment, which may continue to drive the stock higher.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75
NEGATIVE IMPACT
AnaptysBio's stock declined by 25.56% to $22.93, reflecting a negative market response.
The decline indicates negative sentiment or developments, which may continue to impact the stock negatively.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Applied DNA Sciences' stock fell by 37.0% to $0.2, indicating negative market reaction.
The significant drop suggests negative news or sentiment, which could lead to further declines or volatility.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
Cormedix's stock declined by 15.32% to $10.98 following its Q3 earnings report.
The stock's decline is linked to the Q3 earnings report, suggesting disappointing results or outlook that could continue to pressure the stock.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80
NEGATIVE IMPACT
Hims & Hers Health's stock decreased by 15.06% to $18.89, indicating negative market sentiment.
The decline suggests negative sentiment or developments, which may continue to impact the stock negatively.
CONFIDENCE 80
IMPORTANCE 65
RELEVANCE 75
NEGATIVE IMPACT
Option Care Health's stock fell by 20.14% to $24.36 after its Q3 earnings release.
The decline is directly related to the Q3 earnings report, indicating negative results or outlook that may continue to affect the stock.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 85
NEGATIVE IMPACT
Sage Therapeutics' stock decreased by 20.46% to $6.75 following its Q3 earnings report.
The stock's decline is linked to the Q3 earnings report, suggesting disappointing results or outlook that could continue to pressure the stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90